
Intuitive Surgical
ISRG · NASDAQ · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $152 bn
- Div. yield
- —
- Year to date
- −21,7%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
7 ✓ · 1 — · 1 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 52,0 | 69,3 | 25,1 |
| Forward P/E | 35,3 | — | 16,2 |
| PEG | 3,1 | — | 2,2 |
| P/S | 13,3 | 17,3 | 2,2 |
| EV/EBITDA | 42,3 | 62,3 | 17,3 |
| P/FCF | 42,7 | — | 19,5 |
| P/B | 9,5 | 9,4 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 40 analysts
- Buy
- 30
- Hold
- 9
- Sell
- 1
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 2,70 | 3,00 | Up +11,3% |
| Q2 2026 | 2,55 | 2,80 | Up +9,8% |
| Q1 2026 | 2,14 | 2,50 | Up +16,8% |
| Q4 2025 | 2,30 | 2,53 | Up +9,9% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,05 bn | 2,89 bn | 2,77 bn | 2,87 bn | 2,51 bn | 2,44 bn | 2,25 bn | 2,41 bn | 2,04 bn | 2,01 bn | 1,89 bn | 1,93 bn |
| EPS | 1,49 | 2,29 | 2,28 | 2,20 | 1,95 | 1,81 | 1,92 | 1,89 | 1,56 | 1,46 | 1,51 | 1,69 |
| Margin | 17,1% | 28,3% | 29,6% | 27,7% | 28,1% | 27,0% | 31,0% | 28,4% | 27,7% | 26,2% | 28,8% | 31,4% |
| FCF | 1,11 bn | 948 m | 809 m | 730 m | 736 m | 560 m | 465 m | 511 m | 459 m | 311 m | 23,5 m | −207 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $65,4 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| loeb gary10 Nov 2026 · sale | $183 260 | 400 | $458,15 |
| guthart gary s4 Nov 2026 · sale | $4,57 m | 10 000 | $457,34 |
| barratt craig h4 Nov 2026 · sale | $529 003 | 1 150 | $460,00 |
| brosius mark30 Oct 2026 · sale | $28 577 | 63 | $453,60 |
| widman fredrik30 Oct 2026 · sale | $2,38 m | 5 448 | $436,06 |
| brosius mark29 Oct 2026 · sale | $27 319 | 61 | $447,85 |
| brosius mark28 Oct 2026 · sale | $26 938 | 61 | $441,60 |
| brosius mark27 Oct 2026 · sale | $27 549 | 61 | $451,63 |
| brosius mark26 Oct 2026 · sale | $27 557 | 61 | $451,75 |
| widman fredrik23 Oct 2026 · sale | $1,83 m | 4 047 | $453,21 |
| guthart gary s23 Oct 2026 · sale | $9,08 m | 20 095 | $451,61 |
| barratt craig h23 Oct 2026 · sale | $510 370 | 1 150 | $443,80 |
| wadors patricia l23 Oct 2026 · sale | $478 416 | 1 078 | $443,80 |
| widman fredrik15 Sep 2026 · sale | $203 321 | 543 | $374,44 |
| widman fredrik15 Sep 2026 · sale | $204 444 | 546 | $374,44 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NASDAQ
- Country
- US
- IPO date
- 13 Jun 2000
- Website
- www.intuitive.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
MDTMedtronic | $102,88 | 78★★★★★★★★★would consider | 25,1 | +9,8% | 13,9% |
MCKMcKesson | $1 105,04 | 72★★★★★★★★★would consider | 27,3 | +8,2% | 1,1% |
ABTAbbott Laboratories | $107,45 | 33★★★★★★★would not consider | 40,0 | +10,0% | 9,7% |
SYKStryker Corporation | $310,72 | 72★★★★★★★★★would consider | 33,0 | +7,9% | 13,8% |
CVSCVS Health | $88,59 | 83★★★★★★★★★would consider | 10,4 | +6,7% | 2,6% |
Ratio — a score by our methodology, not an investment recommendation.




